Interleukin 2‐induced activation of JAK3: Possible involvement in signal transduction for c‐myc induction and cell proliferation
Open Access
- 5 September 1994
- journal article
- research article
- Published by Wiley in FEBS Letters
- Vol. 351 (2), 201-206
- https://doi.org/10.1016/0014-5793(94)00831-0
Abstract
We have investigated the role of JAK3 in interleukin 2 (IL‐2)‐induced signal transduction with a human T cell line, ED40515(−), lacking expression of the IL‐2 receptor γ chain and its sublines transfected with wild‐type or mutant cDNAs of the IL‐2 receptor γ chain. Our results demonstrated that the membrane‐proximal cytoplasmic region, encompassing the src homology region 2 (SH2)‐like subdomain, of the γ chain is essential for association and activation of JAK3. Furthermore, IL‐2‐induced activation of JAK3 paralleled induction of the c‐myc gene and DNA synthesis but not induction of the c‐fos and c‐jun genes. These results support the hypothesis that JAK3 plays a pivotal role in the IL‐2 receptor‐mediated signals for cell growth.Keywords
This publication has 44 references indexed in Scilit:
- Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinasesFEBS Letters, 1994
- Interleukin-2 Receptor γ Chain: a Functional Component of the Interleukin-4 ReceptorScience, 1993
- Interleukin-2 Receptor γ Chain: a Functional Component of the Interleukin-7 ReceptorScience, 1993
- Identification of JAK2 as a growth hormone receptor-associated tyrosine kinaseCell, 1993
- JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietinCell, 1993
- The IL-2/IL-2 receptor system: A current overviewCell, 1993
- Cloning of the γ Chain of the Human IL-2 ReceptorScience, 1992
- A protein tyrosine kinase in the interferon αβ signaling pathwayCell, 1992
- IL‐2‐dependent in vivo and in vitro tyrosine phosphorylation of IL‐2 receptor γ chainFEBS Letters, 1992
- IL-2 receptor subunit, p75: direct demonstration of its IL-2 binding ability by using a novel monoclonal antibodyInternational Immunology, 1989